An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Trial Profile

An Open Label, Multicenter, Phase II Study to Evaluate Efficacy and Safety of the BiTE Antibody Blinatumomab in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Blinatumomab (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Registrational; Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 27 Apr 2017 According to a National Institute for Health and Care Excellence (NICE) media release, NICE recommends Amgen's BLINCYTO (Blinatumomab) for Adults With Relapsed or Refractory Philadelphia Chromosome-Negative B-Precursor Acute Lymphoblastic Leukaemia.
    • 26 Feb 2017 This trial was completed in Germany according to European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top